CTRI/2012/02/002399招募中3 期
A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexaâ?¢) administered to Indian infants according to a 6-10-14 weeks and a 2-4-6 months schedule.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 224
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All subjects must satisfy ALL the following criteria at study entry:
- •?A male or female between, and including, 6 and 10 weeks of age at the time of the first vaccination.
- •?Documented administration of a hepatitis B vaccine dose at birth.
- •?Subjects who the investigator believes that their parent(s)/legally acceptable representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
- •?Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •?Healthy subjects as established by medical history and clinical examination before entering into the study.
- •?Born after a gestation period of at least 36 weeks.
排除标准
- •The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:
- •?Child in care.
- •?Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose, or planned use during the study period.
- •?Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •?Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, or planned administration during the study period, with the exception of oral human rotavirus (HRV) vaccination which is allowed at any time during the study.
- •?Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •?Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) vaccination or disease, with the exception of a birth dose of hepatitis B vaccine and oral poliovirus vaccine (OPV) as per local standard of care.
- •?Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •?Family history of congenital or hereditary immunodeficiency.
- •?History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- •?Major congenital defects or serious chronic illness.
- •?Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •?Acute disease and/or fever at the time of enrolment.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa™ vaccine in healthy infants in India.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Hib diseases.EUCTR2013-003427-10-Outside-EU/EEAGlaxoSmithKline Biologicals214
进行中（未招募）
不适用
Immunogenicity and safety of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.EUCTR2012-004137-16-Outside-EU/EEAGlaxoSmithKline Biologicals454
进行中（未招募）
1 期
A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy - PRIMAAdvanced follicular lymphomaEUCTR2004-001756-36-GBGELA(RC)1,202
进行中（未招募）
1 期
Safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster (HZ) vaccine when administered under the skin (subcutaneously) vs. into a muscle (intramuscularly) in adults 50 years of age and older.Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults =50 years of age [YOA] and immunocompromised adults =18 YOA)MedDRA version: 14.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-005671-14-GBGlaxoSmithKline Biologicals1,082
进行中（未招募）
不适用
A randomised, multicentre, open-label, phase III study of neoadjuvantlapatinib, trastuzumab, and their combination plus paclitaxel in womenwith HER2/ErbB2 positive primary breast cancer - NeoALTTOWomen with primary ErbB2 overexpressing and/or gene amplified breast cancer > 2 cm diameter who have not undergone previous treatment for invasive breast cancerMedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2006-000564-81-GRGlaxoSmithKline Research and Development Limited450